SLC9A1 and neoplasm: Taken together, our results indicate that the small-molecule inhibitor of NHE1, cariporide, targeted the PDAC stroma in vivo on at least 2 vital fronts; it disrupted the vicious cycle leading to marked fibrosis, and it shifted tumor immune cell infiltrate to a more lymphocytic one, consistent with a more potent antitumor response.